Company Introduction

聖德生技是一間生物技術創業公司，目標致力於革新組織修復技術，減少疤痕及改善慢性傷口癒合。基於對胎兒皮膚如何快速癒合並無疤痕生成的研究基礎上，目前已完成SLI-F06第1階段和第2a階段人體試驗，其可大幅降低手術後疤痕的生成和加速嚴重傷口的癒合。聖德生技由UCLA教授和技術創始人Dr. Chia Soo、Kang Ting和Zhong Zheng共同管理。Dr. Soo擁有超過16年的整形外科臨床經驗和FDA法規專家的經驗。Dr. Ting具備25年的專業知識於跨學科轉化的研究，涉及基礎科學，組織工程和納米科學技術。
Saint Therapeutics is a biotechnology startup focused on revolutionizing tissue repair
and disrupting the billion-dollar scar prevention, scar reduction, and chronic wound healing industries. Building upon over 20 years of research into how fetal skin rapidly heals without scarring, Saint Therapeutics has developed a novel peptide drug, SLI-F06, that significantly reduces scar formation after surgeries and accelerates wound healing.

Brief description of main products or services 

Inspired by fibromodulin found in fetal tissue, Saint Therapeutics has created a novel peptide drug, SLI-F06, that recreates rapid, scar-free fetal-type repair. SLI-F06 activates fibroblasts, the main cell-type responsible for skin and soft tissue healing, making fibroblasts work better (less scarring, stronger wound tensile strength) and faster (more healing) to both decrease scar formation and promote chronic wound healing. SLIF06 is an injectable peptide for use during surgery. It is intended as an acute treatment to allow patients to heal faster, better, and with much less scarring. SLIF06 has completed Phase 1 without drug-related adverse events and Phase 2a with preliminary evidence of significantly improved scar appearance on the treated side at the long-term. Additionally, SLI-F06 is a platform technology that will allow Saint Therapeutics to offer multiple product verticals after tackling the closed wound scar reduction market. These applications include chronic wound healing (e.g. diabetic ulcers), tendon / fascia / muscle healing, and anti-fibrotic coatings.